Metabolic effects of pamidronate in patients with metastatic bone disease

British Journal of Cancer

Volumn 73, Issue 9, 1996, Pages 1089-1095

  Vinholes, J ^a   Guo, C Y ^a   Purohit, O P ^a   Eastell, R ^a   Coleman, R E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonate; Bone metastasis; Bone resorption; Pamidronate; Pyridinium cross link

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM ION; PAMIDRONIC ACID;

ADULT; ANALGESIA; ARTICLE; BONE METASTASIS; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOLYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; URINALYSIS;

EID: 0030010413     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.210     Document Type: Article

References (41)

1. BEHRENS P, KUIRAOKA M, MULLER PK AND ACYL Y. (1995). Pyridinium cross-links as a resorption marker in the diagnosis for osteopathy. Calcif. Tissue Int., 56, 446.
2. BLOMQVIST C, ELOMAA I, RISTELI J, VIRKKUNEN P, PORKKA L, KARONEN SL, RISTELI L AND RISTELI J. (1987). The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy and biochemical markers of bone metabolism. Cancer, 60, 2907-2912.
3. BLUMSOHN A, HANNON R AND EASTELL R. (1995a). Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin. Chem., 41, 318-319.
4. BLUMSOHN A, NAYLOR KE, ASSIRI AMA AND EASTELL R. (1995b). Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin. Chem. 41, 1592-1598.
5. BODY JJ AND DELMAS PD. (1992). Urinary pyridinium cross-links as markers of bone resorption in tumour-associated hypercalcaemia. J. Clin. Endocrinol. Metab., 74, 471-475.
6. BODY JJ, DUMON JC, MENDES M AND LUMEN AA. (1995). Biochemical dose response effects of pamidronate in postmenopausal osteoporosis-evaluation of new markers of bone resorption. Calcif. Tissue Int., 56, 481.
7. BOYCE BF. (1991). Normal bone remodelling and its disruption in metastatic bone disease. In Bone Metastases Diagnosis and Treatment, Rubens RD and Fogelman I (eds), pp. 11-30, Springer: London.
8. BROADUS AE. (1993). Physiological functions of calcium, magnesium, phosphorus and mineral ion balance. In Primers on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Favus MJ (ed), pp. 41-46. Raven Press: New York.
9. CAMPBELL FC, BLAMEY RW, WOOLFSON AMJ, ELSTON CW AND HOSKING DT. (1983). Calcium excretion in metastatic breast cancer. Br. J. Surg., 70, 202.
10. COLEMAN RE. (1994). Evaluation of bone disease in breast cancer. Breast, 3, 73-78.
11. COLEMAN RE AND RUBENS R. (1987). Treatment of hypercalcaemia of malignancy secondary to advanced breast cancer with pamidronate. Br. J. Cancer, 56, 465-469.
12. COLEMAN RE, WHITAKER KD, MOSS DW, MASHITER G, FOGELMAN I AND RUBENS RD. (1988). Biochemical monitoring predicts response in bone to systemic treatment. Br. J. Cancer, 58, 205-210.
13. COLEMAN RE, HOUSTON S, JAMES I, RODGER A, RUBENS RD, LEONARD RCF AND FORD J. (1992). Preliminary results of the use of urinary excretion of pyridinium cross-links for monitoring metastatic bone disease. Br. J. Cancer, 65, 766-768.
14. COLWELL A, RUSSELL RGG AND EASTELL R. (1993). Factors affecting the assay of urinary 3-hydroxy pyridinium cross-links of collagen as markers of bone resorption. Eur. J. Clin Invest., 23, 341-349.
15. CONTE PF, GIANNESSI PG, LATREILLE J, MAURIAC L, KOLIREN L, CLABRESI F AND FORD JM. (1994). Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Ann. Oncol., 5 (suppl. 7), S41-44.
16. EASTELL R. (1994). Biochemical markers. In Spine - State of the Art Reviews, 8: 1, pp. 155-170, Hanley & Belfus: Philadelphia.
17. EYRE DR. (1992). New biomarkers of bone resorption. J. Clin. Endocrinol Metab., 74, 470.
18. EYRE DR, KOOB TJ AND VAN NESS KP. (1984). Quantification of hydroxypyridinium cross-links in collagen by high performance liquid chromatography. Ann. Biochem., 137, 380-388.
19. FLANAGAN AM AND CHAMBERS TJ. (1989). Clodronate inhibits resorption through injury of osteoclast that resorbs clodronate coated bone. Bone Miner., 6, 33-43.
20. GARNERO P, GRIMAUX M, SEGUIN P AND DELMAS P. (1994a). Characterisation of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone. Miner. Res., 9, 255-264.
21. GARNERO P, GINEYTS E, RIOU JP AND DELMAS PD (1994b). Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin. Endocrinol. Metab., 79, 780-785.
22. GARRET R. (1993). Bone destruction in cancer. Semin. Oncol., 20 (suppl. 2), 4-9.
23. HANSON DA, WEIS MAE, BOLLEN AM, MASLAN SL, SINGER FR AND EYRE DR. (1992). A specific immunoassay for monitoring human bone resorption: quantification of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res., 7, 1251-1258.
24. LAHTINEN R, LAASKO M, PALVA I, VIRKKUEN P, AND ELOMAA I FOR THE FINNISH LEUKAEMIA GROUP. (1992). Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet. 340, 1049.
25. LI F, PITT PI, SHERWOOD R, BARRETT J, HOUGHTON J, PARSONS V AND MONIZ C. (1993). Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. Eur. J. Clin. Invest., 23, 566-571.
26. LIPTON A, DEMERS L, DANILOFF Y, CURLEY E, HAMILTON C, HARVEY H, WITTERS L, SEAMAN J, VAN DER GIESSEN R AND SEYEDIN S. (1993). Increased urinary excretion of pyridinium cross-links in cancer patients. Clin. Chem., 39, 614-618.
27. LIPTON A, GLOVER D, HARVEY H, GRABELSKY S, ZELENAKAS K, MACERATA R AND SEAMAN J. (1994). Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann. Oncol., 5 (suppl. 7), 31-35.
28. LOWIK CWGM, VAN DER PLUIJM G AND BIJVOET OLM. (1988). Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts, the effects of a bisphosphonate. J. Bone Miner. Res., 3, 185-192.
29. MARTONI A, GUARALDI M, CAMERA P, BIAGI R, MARRI S, BEGHE F AND PANNUTI F. (1991). Controlled clinical study on the use of dichloromethylene disphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncol., 48, 97-101.
30. MUNDY G. (1995). Metastatic bone disease. In Bone Remodelling and its Disorders, Mundy G (ed), pp. 104-122, Martin Dunitz: London.
31. O'ROURKE N, MCCLOSKEY E, HOUGHTON F, HUSS H AND KANIS JA. (1995). Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J. Clin. Oncol., 13, 929-934.
32. PATERSON AHG, POWLES TJ, KANIS JA, MCCLOSKEY E, HANSON J AND ASHLEY S. (1993). Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol., 11, 59-65.
33. PECHERSTORFER M, SCHILING T, JANISCH S, WOLOSZCZUK W, BAUMGARTNER G, ZIEGLER R AND OGRIS E. (1993). Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J. Nucl. Med., 34, 1039-1044.
34. PECHERSTORFER M, LUDWIG H, ZIMMER-ROTH, SCHILING T, WOITGE HW, SCHIMIDT H, BAUMGARTNER G, THIEBAUD D AND SEIBEL M. (1995). The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J. Clin. Endocrinol. Metab., 80, 97-103.
35. PUROHIT OP, ANTHONY C, OWEN J, RADSTONE CR AND COLEMAN RE. (1994). High-dose intravenous pamidronate for metastatic bone pain. Br. J. Cancer, 70, 554-558.
36. REID IR, WATTIE DJ, EVANS MC, GAMBLE GD, STAPLETON JP AND CORNISH J. (1994). Continuous therapy with pamidronate. a potent bisphosphonate, in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab., 79, 1595-1599.
37. ROSALKI SB AND FOO AY. (1984). Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin. Chem., 30, 1182-1186.
38. SEIBEL MJ, LAMBRINOUDARI IL AND ZIPF A. (1994). Biochemical markers of bone metabolism in metastatic bone disease. In Metastatic Bone Disease, Diel J, Kaufmann M and Bastert G. (eds), pp. 108-125. Springer-Verlag: Berlin.
39. THIEBAUD D, LEYVRAZ S, VON FLIEDNER V, PERCY L AND BURCKHARDT P. (1991). Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur. J. Cancer, 27, pp. 37-41.
40. VAN HOLTEN-VERZANTVOORT ATM, KROON HM, BIJVOET OLM, CLETON FJ, BEEX LVAM, BLIJHAM G, HERMANS J, NEIJT JP, PAPAPOULOS SE, SLEEBOOM HP, VERMEY P AND ZWINDERMAN AH. (1993). Palliative pamidronate treatment in patients with bone metastases from breast cancer. J. Clin. Oncol., 11, 491-498.
41. VINHOLES J, PUROHIT OP, GUO CY, EASTELL R AND COLEMAN R. (1995). Randomised double-blind comparison of pamidronate or clodronate for hypercalcaemia of malignancy: effects on bone metabolism markers. Eur. J. Cancer. 31A (suppl. 5), S253.